edoc

Items where contributor is "Matter-Walstra, Klazien Wietske"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 | 1996 | 1985

2015

Matter-Walstra, K. W. and Greiner, M. and Cusini, A. and Schiesser, M. and Ledergerber, B. and Fehr, T. and Mueller, N. J.. (2015) Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transplant infectious disease, Vol. 17, H. 3. S. 342-349.

Matter-Walstra, K. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2015) Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons : SAKK 89/09. Oncology, 88 (1). pp. 18-27.

Köberle, D. and Betticher, D. C. and von Moos, R. and Dietrich, D. and Brauchli, B. and Baertschi, D. and Matter, K. and Winterhalder, R. and Borner, M. and Anchisi, S. and Moosmann, P. and Kollar, A. and Saletti, P. and Roth, A. and Frueh, M. and Kueng, M. and Popescu, R. A. and Schacher, S. and Hess, V. and Herrmann, R.. (2015) Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26 (4). pp. 709-714.

Kovacevic, A. and Dragojecic-Simic, V. and Rancic, N. and Jurisevic, M. and Gutzwiller, F. and Matter-Walstra, K. and Jakovljevic, M.. (2015) End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl, 72 (4). pp. 334-341.

2014

Matter-Walstra, K. and Klingbiel, D. and Szucs, T. and Pestalozzi, B. C. and Schwenkglenks, M.. (2014) Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? PharmacoEconomics, Vol. 32, no. 6. S. 591-599.

Matter-Walstra, K. M. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Schwenkglenks, M. and Pestalozzi, B. C.. (2014) Delivery of health care at the end of life in cancer patients of four swiss cantons : a retrospective database study (SAKK 89/09). BMC cancer, Vol. 14. S. 306-317.

Jakovljevic, Mihajlo and Gutzwiller, Florian S. and Schwenkglenks, Matthias and Milovanovic, Olivera and Rancic, Nemanja and Varjacic, Mirjana and Stojadinovic, Dobrivoje and Dagovic, Aleksandar and Matter-Walstra, Klazien. (2014) Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19 (3). pp. 1111-1120.

Joerger, M. and Schaer-Thuer, C. and Koeberle, D. and Matter-Walstra, K. and Gibbons-Marsico, J. and Diem, S. and Thuerlimann, B. and Cerny, T.. (2014) Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. European Journal of Clinical Pharmacology, 70 (6). p. 719.

2012

Matter-Walstra, Klazien and Joerger, Markus and Kühnel, Ursula and Szucs, Thomas and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system. Value in health, Vol. 15, H. 1. S. 65-71.

2011

Joerger, M. and Matter-Walstra, K. and Früh, M. and Kühnel, U. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis. Annals of oncology, Vol. 22, H. 3. S. 567-74.

2010

Matter-Walstra, K. W. and Dedes, K. J. and Schwenkglenks, M. and Brauchli, P. and Szucs, T. D. and Pestalozzi, B. C.. (2010) Trastuzumab beyond progression : a cost-utility analysis. Annals of oncology, Vol. 21, H. 11. S. 2161-2168.

2009

Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Pestalozzi, Bernhard C. and Fink, Daniel and Brauchli, Peter and Szucs, Thomas D.. (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer : an economic evaluation. EJC : European journal of cancer, Vol. 45, H. 8. S. 1397-1406.

2008

Matter-Walstra, Klazien and Schoeni-Affolter, Franziska and Widmer, Marcel and Busato, André. (2008) Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. Journal of Evaluation in Clinical Practice , 14 (1). pp. 75-82.

2007

Schoeni-Affolter, F. and Matter-Walstra, K. and Widmer, M. and Busato, A.. (2007) Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach. Complementary Medicine Research, 14 (6). pp. 346-352.

2006

Matter-Walstra, K. and Widmer, M. and Busato, A.. (2006) Seasonal variation in orthopedic health services utilization in Switzerland: the impact of winter sport tourism. BMC Health Services Research, 6. p. 25.

Matter-Walstra, Klazien and Widmer, Marcel and Busato, André. (2006) Analysis of patient flows for orthopedic procedures using small area analysis in Switzerland. BMC Health Services Research, 6. p. 119.

2001

Matter-Walstra, K. W. and Hoffrage, U.. (2001) Individuelle Entscheidungsfindung am Beispiel der Brustkrebs-Früherkennung: Erfahrungen aus Fokusgruppen in der Schweiz. Care Management, 3 (5). pp. 26-29.

1996

Matter-Walstra, K. W. and Kraft, R.. (1996) Atypical cells in effusions: diagnostic value of cell image analysis combined with immunocytochemistry. Diagn Cytopathol, 15 (4). pp. 263-269.

1985

Walstra, K. and Gratwohl, A. and Riederer, I. and Speck, B.. (1985) B/T cell ratio of rabbit peripheral blood lymphocytes : influence of separation technique on results. Journal of immunological methods, Vol. 79, H. 1. S. 143-147.